Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of ...

Travere Therapeutics said Chief Research Officer William Rote plans to retire from the company in February. Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Mornings like we had on Wednesday are exactly why I get up and ...

Piper Sandler analyst Allison Bratzel maintained a Buy rating on Abivax SA Sponsored ADR today and set a price target of $165.00. Claim 55% Off TipRanks. Unlock powerful investing ...

AZN's Ultomiris wins FDA priority review for IgAN, backed by late-stage data showing a 43.4% proteinuria reduction versus ...

Fresh off a deal with Travere Therapeutics Inc. for civorebrutinib worth more than $1.14 billion, Everest Medicines Ltd. went on a shopping spree, striking three deals in six days to expand its ...

Compare risk profiles, sector concentration, and income potential as these two healthcare ETFs take different approaches to ...

Discover the latest in biotechnology with press releases highlighting innovations, research, and developments driving biotech's future. Stay informed on advancements changing biotech and explore ...